KB-1398

BI-1808-hIgG1

Home » Antibody » BI-1808-hIgG1

Background

BI-1808, an IgG1 monoclonal antibody of human origin, is designed to selectively target TNFR2 by disrupting its interaction with the ligand TNF-¦Á. This action facilitates the Fc¦ÃR-dependent elimination of intratumoral regulatory T cells (Tregs) while concurrently fostering the proliferation of intratumoral CD8+ T cells. In preclinical studies involving immunocompetent mice bearing tumors and displaying partial sensitivity to checkpoint blockade, the co-administration of BI-1808 with surrogate antibodies mimicking anti-PD-1 resulted in complete remission across all treated mice. This observed outcome suggests a potential synergistic effect between these agents, culminating in the complete cure of the subjects.

Specifications

Catalog Number:
KB-1398
Cell Line Name:
BI-1808-hIgG1
Price:
0
Host Cell Line:
EXPI-CHO
Target:
TNFR2
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2¦Ìm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20¡ãC to -80¡ãC; Stored at 2-8¡ãC for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1. Rauert H, Wicovsky A, Muller N, Siegmund D, Spindler V, Waschke J, et al.. Membrane Tumor Necrosis Factor (TNF) Induces P100 Processing via TNF Receptor-2 (TNFR2). J Biol Chem (2010) 285:7394¨C404. 2. Shamdani S, Uzan G, Naserian S. TNFalpha-TNFR2 Signaling Pathway in Control of the Neural Stem/Progenitor Cell Immunosuppressive Effect: Different Experimental Approaches to Assess This Hypothetical Mechanism Behind Their Immunological Function. Stem Cell Res Ther (2020) 11:307.
Please enable JavaScript in your browser to complete this form.